Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal

Showing results (261-270 of 276) with videos related to

Pageof 28
Sort By:
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Nature Communications|March 2, 2018
Single cell polarity in liquid phase facilitates tumour metastasisAnna Lorentzen, Paul F Becker, Jan Kosla, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic MelanomaInês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
Pageof 28

Showing results (261-270 of 276) with videos related to

Sort By:
Pageof 28
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Nature Communications|March 2, 2018
Single cell polarity in liquid phase facilitates tumour metastasisAnna Lorentzen, Paul F Becker, Jan Kosla, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic MelanomaInês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
Pageof 28